ImmuPharma plc (LON:IMM – Get Free Report)’s stock price was up 8% on Thursday. The company traded as high as GBX 4.30 and last traded at GBX 3.97. Approximately 1,687,495 shares were traded during mid-day trading, a decline of 31% from the average daily volume of 2,456,595 shares. The stock had previously closed at GBX 3.67.
ImmuPharma Trading Down 17.8%
The business’s fifty day simple moving average is GBX 3.64 and its 200 day simple moving average is GBX 4.75. The stock has a market cap of £20.04 million, a price-to-earnings ratio of -3.86 and a beta of 3.02.
ImmuPharma (LON:IMM – Get Free Report) last released its earnings results on Tuesday, September 15th. The company reported GBX (0.84) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 559.87%. As a group, research analysts anticipate that ImmuPharma plc will post -339.00 earnings per share for the current year.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Recommended Stories
- Five stocks we like better than ImmuPharma
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
- The Factories Behind AI Servers Just Raised Their Outlooks—3 Contract Manufacturers to Watch
- MarketBeat Week in Review – 10/26 – 10/30
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
